2022
SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts
Park LS, McGinnis KA, Gordon KS, Justice AC, Leyden W, Silverberg MJ, Skarbinski J, Jefferson C, Horberg M, Certa J, Napravnik S, Edwards JK, Westreich D, Bastarache L, Gangireddy S, Benning L, D'Souza G, Williams C, Althoff KN. SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 249-255. PMID: 35195574, PMCID: PMC9203911, DOI: 10.1097/qai.0000000000002943.Peer-Reviewed Original ResearchConceptsSARS-CoV-2SARS-CoV-2 testingHIV statusClinical cohortPositive SARS-CoV-2 testSARS-CoV-2 positivitySARS-CoV-2 testCOVID-19-related outcomesProportion of PWHProportion of patientsSARS-CoV-2 variantsCOVID-19 vaccineLatest therapeutic optionsTherapeutic optionsUS cohortPositivity proportionInterval cohortPWHPWOHCohortHealth systemDiverse cohortHIVPositivityTesting proportions
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh risk
2010
CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?
Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC, for the North American AIDS Cohort Collaboration on Research and Design. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? AIDS Research And Therapy 2010, 7: 45. PMID: 21159161, PMCID: PMC3022663, DOI: 10.1186/1742-6405-7-45.Peer-Reviewed Original ResearchCD4 countHIV careRace/ethnicityFirst presentationNorth American AIDS Cohort CollaborationHIV transmission risk groupAge groupsAdvanced HIV diseaseHIV testing effortsLow CD4 countTransmission risk groupsMean CD4 countMedian CD4 countHIV transmission riskCohort CollaborationHIV diseaseInitial presentationRisk groupsClinical cohortProportion of individualsTransmission riskOlder individualsYoung adultsCohortYoung individuals